LLY · 10-Q · 2026Q2 · Full report

Revenue Concentration Risk

ELI LILLY & Co · 2026-08-05 · Importance 56 · Surprise 24

Mounjaro and Zepbound accounted for 65% of Lilly's total revenue for the six months ended June 30, 2026. The two products generated approximately $27.7 billion of combined six-month revenue based on reported product revenue of $18.605 billion for Mounjaro and $9.088 billion for Zepbound. Incretin volume fluctuations from channel dynamics or demand can therefore have a disproportionate impact on results in any period. Lilly launched Foundayo in the U.S. during the second quarter and is expanding manufacturing capacity to support current and prospective incretin demand.